Sign inJoin waitlistJoin the waitlist

SF

Scott Fretzin

Adjunct Clinical Assistant Professor of Dermatology · Indiana University School of Medicine

Credentials: · · ·

History

Indiana University School of Medicine
Present

Dermatology
1994–1997
Preliminary or Transitional Year
1993–1994
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1989–1993

Research

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
The Lancet · 2009 · 448 citations
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
Journal of Allergy and Clinical Immunology · 2012 · 327 citations
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
British Journal of Dermatology · 2018 · 93 citations

Alice Gottlieb
2 papers
CR
Caitriona Ryan
2 papers
DF
David Fretzin
2 papers
JC
Jennifer Cather
2 papers
Kristina Duffin
2 papers · 1 as a resident
MM
Martin Menter
2 papers
Aaron Mangold
1 paper
Alexa Kimball
1 paper
AB
Andrew Blauvelt
1 paper
April Armstrong
1 paper
Arthur Kavanaugh
1 paper
BG
Bernard Goffe
1 paper

Clinical trials

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2027
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2028